The 2013 Annual Report for The Leukemia & Lymphoma Society (LLS) has been released. In this series of blogs, a number of key advancements and developments will be highlighted. This report is an in-depth look at how your fundraising dollars are being spent and the medical breakthroughs and partnerships you are so crucial in creating.
This unprecedented Blood Cancer Research Partnership will bring clinical trials to patients where they live and address one of the primary bottlenecks to new cancer therapies: the need for more patients to take part in trials.
LLS committed funding to Valor Biotherapeutics, LLC, a joint venture between ImmunGene and Caliber companies, to develop a novel protein therapeutic that may improve outcomes for many patients with indolent lymphomas who do not respond to standard therapy with Rituxan. Valor's biotherapeutic is produced by fusing lymphoma-seeking antibodies to tumor-cell-killing proteins in a single, genetically engineered molecule.
The APL Project: LLS initiated a project with Anand Jillella, MD, Chief of Hematology, Oncology and Bone Marrow Transplant at Emory University, to reduce the mortality rates for patients diagnosed with acute promyelocytic leukemia (APL) by providing community oncologists/hematologists with a simple, optimized treatment protocol for the care of newly diagnosed patients with APL, a rare molecular subtype of acute myeloid leukemia.
LLS partnered with Affimed Therapeutics AG to co-fund a phase 2 trial of a novel multi-targeted anitbody in Hodgkin's lymphoma (HL) patients for whom currently available treatments have failed. This therapeutic is directed against two different molecules, CD30 and CD16A, to bring cancer-killing immune cells directly to the HL cells. It is a first-in-class immunotherapy designed to treat HL patients and patients with other CD30-positive malignancies.
No comments:
Post a Comment